Multi-Targeting Anticancer Activity of a New 4-Thiazolidinone Derivative with Anti-HER2 Antibodies in Human AGS Gastric Cancer Cells

Combining chemotherapy with immunotherapy still remains a regimen in anticancer therapy. Novel 4-thiazolidinone-bearing hybrid molecules possess well-documented anticancer activity, and together with anti-HER2 antibodies, may represent a promising strategy in treating patients with gastric cancer with confirmed human epidermal growth factor receptor 2 (HER2) expression. The aim of the study was to synthesize a new 4-thiazolidinone derivative (Les-4367) and investigate its molecular mechanism of action in combination with trastuzumab or pertuzumab in human AGS gastric cancer cells. AGS cell viability and antiproliferative potential were examined. The effect of the tested combinations as well as monotherapy on apoptosis and autophagy was also determined. Metalloproteinase-2 (MMP-2), intercellular adhesion molecule 1 (ICAM-1), pro-inflammatory and anti-inflammatory cytokine concentrations were also demonstrated by the ELISA technique. We proved that pertuzumab and trastuzumab were very effective in increasing the sensitivity of AGS gastric cancer cells to novel Les-4367. The molecular mechanism of action of the tested combination is connected with the induction of apoptosis. Additionally, the anticancer activity is not associated with the autophagy process. Decreased concentrations of pro-inflammatory cytokines, MMP-2 and ICAM-1—were observed. The novel combination of drugs based on anti-HER2 antibodies with Les-4367 is a promising strategy against AGS gastric cancer cells.

[1]  R. Lesyk,et al.  4-Thiazolidinone-Bearing Hybrid Molecules in Anticancer Drug Design , 2022, International journal of molecular sciences.

[2]  Y. M. Lee,et al.  Expression of ICAM-1 in Blood Vascular Endothelium and Tissues in Human Premalignant Lesion and Gastric/Hepatocellular Carcinomas. , 2022, The Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi.

[3]  J. Handzlik,et al.  2-{5-[(Z,2Z)-2-Chloro-3-(4-nitrophenyl)-2-propenylidene]-4-oxo-2-thioxothiazolidin-3-yl}-3-methylbutanoic Acid as a Potential Anti-Breast Cancer Molecule , 2022, International journal of molecular sciences.

[4]  Agnieszka Gornowicz,et al.  Anti-HER2 monoclonal antibodies intensify the susceptibility of human gastric cancer cells to etoposide by promoting apoptosis, but not autophagy , 2021, PloS one.

[5]  R. Lesyk,et al.  Autophagy Modulators in Cancer Therapy , 2021, International journal of molecular sciences.

[6]  Q. Guo,et al.  FV-429 induces autophagy blockage and lysosome-dependent cell death of T-cell malignancies via lysosomal dysregulation , 2021, Cell death & disease.

[7]  Y. Bang,et al.  First-line pembrolizumab/placebo plus trastuzumab and chemotherapy in HER2-positive advanced gastric cancer: KEYNOTE-811 , 2020, Future oncology.

[8]  M. Cecchini,et al.  Targeted Therapies in Advanced Gastric Cancer , 2020, Current Treatment Options in Oncology.

[9]  Agnieszka Gornowicz,et al.  The Effect of Novel 7-methyl-5-phenyl-pyrazolo[4,3-e]tetrazolo[4,5-b][1,2,4]triazine Sulfonamide Derivatives on Apoptosis and Autophagy in DLD-1 and HT-29 Colon Cancer Cells , 2020, International journal of molecular sciences.

[10]  Agnieszka Gornowicz,et al.  Monoclonal anti-MUC1 antibody with novel octahydropyrazino[2,1-a:5,4-a′]diisoquinoline derivative as a potential multi-targeted strategy in MCF-7 breast cancer cells , 2019, Oncology reports.

[11]  Funda Meric-Bernstam,et al.  Advances in HER2-Targeted Therapy: Novel Agents and Opportunities Beyond Breast and Gastric Cancer , 2018, Clinical Cancer Research.

[12]  M. Shah,et al.  Pertuzumab plus trastuzumab and chemotherapy for HER2-positive metastatic gastric or gastro-oesophageal junction cancer (JACOB): final analysis of a double-blind, randomised, placebo-controlled phase 3 study. , 2018, The Lancet. Oncology.

[13]  W. Jia,et al.  Liquid biopsies to track trastuzumab resistance in metastatic HER2-positive gastric cancer , 2018, Gut.

[14]  L. Shen,et al.  Evolutionary Expression of HER2 Conferred by Chromosome Aneuploidy on Circulating Gastric Cancer Cells Contributes to Developing Targeted and Chemotherapeutic Resistance , 2018, Clinical Cancer Research.

[15]  N. Finiuk,et al.  5-Ene-4-thiazolidinones induce apoptosis in mammalian leukemia cells. , 2016, European journal of medicinal chemistry.

[16]  R. Lesyk,et al.  Synthetic approaches, structure activity relationship and biological applications for pharmacologically attractive pyrazole/pyrazoline–thiazolidine-based hybrids , 2016, European Journal of Medicinal Chemistry.

[17]  Hai-wei Zhang,et al.  FV‐429 Induced Apoptosis Through ROS‐Mediated ERK2 Nuclear Translocation and p53 Activation in Gastric Cancer Cells , 2015, Journal of cellular biochemistry.

[18]  P. Tassone,et al.  A phase IIa dose-finding and safety study of first-line pertuzumab in combination with trastuzumab, capecitabine and cisplatin in patients with HER2-positive advanced gastric cancer , 2014, British Journal of Cancer.

[19]  Sharmila Anandasabapathy,et al.  Gastric Cancer: Descriptive Epidemiology, Risk Factors, Screening, and Prevention , 2014, Cancer Epidemiology, Biomarkers & Prevention.

[20]  W. Kielan,et al.  Caspases and their role in gastric cancer. , 2013, Advances in clinical and experimental medicine : official organ Wroclaw Medical University.

[21]  N. Freedman,et al.  Body mass index in relation to oesophageal and oesophagogastric junction adenocarcinomas: a pooled analysis from the International BEACON Consortium , 2012, International journal of epidemiology.

[22]  Y. Mok,et al.  Expression of Intercellular Adhesion Molecule-1 and E-Selectin in Gastric Cancer and Their Clinical Significance , 2012, Journal of gastric cancer.

[23]  A. Giraud,et al.  Targeting STAT3 in gastric cancer , 2012, Expert opinion on therapeutic targets.

[24]  D. Forman,et al.  Pickled Food and Risk of Gastric Cancer—a Systematic Review and Meta-analysis of English and Chinese Literature , 2012, Cancer Epidemiology, Biomarkers & Prevention.

[25]  T. Hirayama,et al.  Interweaving MicroRNAs and Proinflammatory Cytokines in Gastric Mucosa with Reference to H. pylori Infection , 2012, Journal of Clinical Immunology.

[26]  Jaejoon Jung,et al.  MMP-2 as a putative biomarker for carcinomatosis in gastric cancer. , 2011, Hepato-gastroenterology.

[27]  J. Rubenstein,et al.  Meta‐analysis: the association of oesophageal adenocarcinoma with symptoms of gastro‐oesophageal reflux , 2010, Alimentary pharmacology & therapeutics.

[28]  Yoon-Koo Kang,et al.  Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial , 2010, The Lancet.

[29]  R. Hunt,et al.  Asia–Pacific consensus guidelines on gastric cancer prevention , 2008, Journal of gastroenterology and hepatology.

[30]  M. Moasser.  The oncogene HER2: its signaling and transforming functions and its role in human cancer pathogenesis , 2007, Oncogene.

[31]  D. L. Preston,et al.  Solid Cancer Incidence in Atomic Bomb Survivors: 1958–1998 , 2007, Radiation research.

[32]  C. Haglund,et al.  MMP-2 but not MMP-9 associated with COX-2 and survival in gastric cancer , 2006, Journal of Clinical Pathology.

[33]  D. Albanes,et al.  Tooth loss is associated with increased risk of gastric non-cardia adenocarcinoma in a cohort of Finnish smokers , 2005, Scandinavian journal of gastroenterology.

[34]  S. Beghelli,et al.  Family history of gastric cancer: a correlation between epidemiologic findings and clinical data , 2005, Gastric Cancer.

[35]  Shohei Koyama,et al.  Expression of intercellular adhesion molecule 1 (ICAM-1) during the development of invasion and/or metastasis of gastric carcinoma , 2005, Journal of Cancer Research and Clinical Oncology.

[36]  C. Abnet,et al.  Prospective study of tooth loss and incident esophageal and gastric cancers in China , 2001, Cancer Causes and Control.

[37]  K. Orita,et al.  ICAM‐1 expression and the soluble ICAM‐1 level for evaluating the metastatic potential of gastric cancer , 2002, International journal of cancer.

[38]  S. Thompson.  Advances in experimental medicine and biology , 1996 .

[39]  Y. Hinoda,et al.  Detection of circulating intercellular adhesion molecule‐1 antigen in malignant diseases , 1991, Clinical and experimental immunology.

[40]  S. Ferrone,et al.  Differential expression of intercellular adhesion molecule 1 in primary and metastatic melanoma lesions. , 1990, Cancer research.